Related Experiment Video

Updated: Jun 26, 2026

Seven Steps to Stellate Cells
06:40

Seven Steps to Stellate Cells

Published on: May 10, 2011

Inverse association between hepatic stellate cell apoptosis and fibrosis in chronic hepatitis C virus infection

S A Gonzalez1, M I Fiel, J Sauk

  • 1Center for the Study of Hepatitis C and Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York 10065, USA.

Insights

In chronic hepatitis C virus (HCV) infection, reduced apoptosis of hepatic stellate cells (HSC) is linked to liver fibrosis progression. This study found fewer apoptotic HSC in HCV patients, especially those with advanced fibrosis.

Area of Science:

  • Hepatology
  • Cell Biology
  • Fibrosis Research

Background:

  • Hepatic stellate cells (HSC) are key in liver fibrogenesis.
  • HSC apoptosis is a primary clearance mechanism in animal models, but human data are limited.
  • Understanding HSC apoptosis in chronic hepatitis C virus (HCV) infection is crucial for fibrosis progression insights.

Purpose of the Study:

  • To investigate the association between HSC apoptosis and liver fibrosis stage in chronic HCV infection.
  • To compare HSC apoptosis rates in HCV-infected individuals versus healthy controls.
  • To explore the role of HSC apoptosis in the progression of liver fibrosis in HCV patients.

Main Methods:

  • Cross-sectional study of 44 HCV-positive subjects and 9 HCV-negative controls.
  • Immunohistochemistry used to identify activated (alpha-smooth muscle actin+), proliferative (Ki-67+), and apoptotic (TdT-mediated dUTP nick end-labeling+) HSC in liver biopsies.
  • Cell enumeration performed per high-power field (HPF) by a single pathologist.

Main Results:

  • HSC apoptosis was significantly lower in HCV-positive subjects compared to controls (P=0.02).
  • Among HCV-positive subjects, HSC apoptosis decreased with increasing fibrosis stage (P=0.04).
  • Multivariate analysis showed HSC apoptosis decreased by 0.14 cells/HPF per fibrosis stage increase (P=0.04).

Conclusions:

  • Reduced HSC apoptosis is observed in chronic HCV infection.
  • Inhibition of HSC apoptosis may contribute to liver fibrosis progression in HCV patients.
  • Findings suggest targeting HSC apoptosis as a therapeutic strategy for liver fibrosis.

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...